We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

New COVID-19 Rapid Test Identifies Antibody Effectiveness Against Multiple SARS-CoV-2 Variants

By LabMedica International staff writers
Posted on 06 Dec 2021
Print article
Image: New COVID-19 rapid test identifies antibody effectiveness against multiple SARS-CoV-2 variants (Photo courtesy of Duke University)
Image: New COVID-19 rapid test identifies antibody effectiveness against multiple SARS-CoV-2 variants (Photo courtesy of Duke University)

A new test can quickly and easily assess how well a person’s neutralizing antibodies fight infection from multiple variants of COVID-19 such as Delta and the newly discovered Omicron variant.

The test devised by biomedical engineers at Duke University (Durham, NC, USA) could potentially tell doctors how protected a patient is from new variants and those currently circulating in a community or, conversely, which monoclonal antibodies to treat a COVID-19 patient. The researchers have dubbed their test the COVID-19 Variant Spike-ACE2-Competitive Antibody Neutralization assay, or CoVariant-SCAN for short. The test’s technology hinges on a polymer brush coating that acts as a sort of non-stick coating to stop anything but the desired biomarkers from attaching to the test slide when wet. The high effectiveness of this non-stick shield makes the test incredibly sensitive to even low levels of its targets. The approach allows researchers to print different molecular traps on different areas of the slide to catch multiple biomarkers at once.

In this application, the researchers print fluorescent human ACE2 proteins—the cellular targets of the virus’s infamous spike protein—on a slide. They also print spike proteins specific to each variant of COVID-19 at different specific locations. When the test is run, the ACE2 proteins detach from the slide and are caught by the spike proteins still attached to the slide, causing the slide to glow. But in the presence of neutralizing antibodies, the spike proteins are no longer able to grab on to the ACE2 proteins, making the slide glow less, indicating the effectiveness of the antibodies. By printing different variants of the COVID-19 spike protein on different portions of the slide, researchers can see how effective the antibodies are at preventing each variant from latching onto their human cellular target simultaneously.

While they produce similar results, the critical difference between the CoVariant-SCAN and current methods is the speed and ease with which it can produce results. Typical current approaches require isolating live virus and culturing cells, which can take 24 hours or more and requires a wide variety of safety precautions and specially trained technicians. The CoVariant-SCAN, in contrast, does not require live virus, is easy to use in most settings and takes less than an hour—potentially just 15 minutes—to produce accurate results. Moving forward, the researchers are working to streamline the technique into a microfluidic chip that could be mass produced and report results with only a few drops of blood, plasma or other liquid sample containing antibodies. This approach has already been proven to work on a similar test that can distinguish COVID-19 from other coronaviruses.

“We would love to have real-time visibility of the emerging variants and understand who still has functional immunity,” said Cameron Wolfe, associate professor of medicine at the Duke University School of Medicine. “Additionally, this hints that there might be a technique whereby you could quickly assess which synthetic monoclonal antibody might be best to administer to a patient with a particular emergent variant. Currently we really have no real-time way of knowing that, so we rely on epidemiological data that can track weeks behind.”

“The reverse is also true. To be able to pre-screen an individual's antibodies and predict whether they were sufficiently protected against a particular variant they are perhaps about to run into while travelling, or that is emerging in their area. We have no way of doing that at the present time. But a test like the CoVariant-SCAN could make all of these scenarios possible,” added Wolfe.

Related Links:
Duke University 

Platinum Supplier
SARS-CoV-2 Pooling Test
Extensive SARS-CoV-2 Pooling
Electrolyte Analyzer
Portable Tube Luminometer
Junior LB 9509
POC Clinical Chemistry Analyzer

Print article
IIR Middle East


Molecular Diagnostics

view channel
Image: The ultrarapid genome sequencing pipeline, indicating all processes from sample collection to a diagnosis. Vertically stacked processes are run in parallel (Photo courtesy of Stanford University)

Ultrarapid Nanopore Genome Sequencing in a Critical Care Setting

A genetic diagnosis can guide clinical management and improve prognosis in critically ill patients, and much effort has gone into developing methods that result in rapid, reliable results.... Read more


view channel
Image: My Qualiris QC (Photo courtesy of Stago)

Stago Launches New My Qualiris QC Website for Brand-New User Experience

Stago (Paris, France) has launched its new My Qualiris QC website which provides a brand-new user experience with a 24/7 accessible web-application where the results of a user’s network are only a few clicks away.... Read more


view channel

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.